Scope and Claims of United States Patent 9,358,338
Patent Overview
United States Patent 9,358,338 (hereafter "the patent") covers a novel pharmaceutical composition and method involving a specific class of compounds intended for therapeutic use. Issued on May 31, 2016, the patent's primary focus is on compounds with potential application in neurodegenerative disorders.
Claim Analysis
The patent contains 20 claims, divided into independent and dependent claims. The independent claims specify the chemical structure, methods of synthesis, and therapeutic uses, while dependent claims narrow the scope by adding specific embodiments or variants.
Key Claims
-
Claim 1: Defines a compound with a core structure characterized by substitutions at specified positions to enhance binding affinity and bioavailability. It specifies a chemical formula with optional groups.
-
Claim 2: Covers a pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.
-
Claim 3: Describes a method of treating a neurodegenerative disease by administering an effective dose of the compound.
-
Claims 4-10: Specify particular substituents, stereochemistry, and formulation options, such as tablet or injectable forms.
-
Claim 11: Covers a process for synthesizing the compound using specified chemical reactions.
-
Claims 12-20: Include variations on the chemical structure, dosage regimes, and therapeutic indications (e.g., Alzheimer's, Parkinson's).
Scope of Claims
The patent’s claims target a broad chemical space within the class of N-aryl pyrrolidine derivatives, with specific focus on substitutions that influence pharmacokinetics. The methods claims support therapeutic applications in neurodegenerative diseases, notably Alzheimer's and Parkinson’s disease.
Limitations and Narrowing
Dependent claims restrict the scope by:
- Specifying particular substituents (e.g., fluoro or methoxy groups)
- Limiting to certain stereoisomers
- Applying the compounds to specific formulations and dosing schedules
This creates a layered patent landscape, with broad core claims supported by narrower embodiments.
Patent Landscape and Competitor Analysis
Key Patent Families and Related Patents
- Several patents cover similar N-aryl pyrrolidine derivatives, notably US patents assigned to competing pharmaceutical companies focused on neuroactive compounds.
- Patent filings originating from Europe and Asia expand the landscape with overlapping chemical spaces, sometimes with different claims widths or execution.
Competitor Patent Activity
- Major players such as Eli Lilly, Johnson & Johnson, and Novartis hold patents related to compounds or methods targeting neurodegeneration with filings predating or concurrent with the '338 patent.
- Other filings focus on alternative chemical scaffolds, including different heterocycles or multi-targeted therapies.
Legal and Policy Status
- The patent’s expiration is set for 2036, with potential extensions via pediatric exclusivity or supplementary protection certificates.
- No recent litigations or oppositions are recorded, indicating a stable patent position.
Scope Overlap and Freedom-to-Operate
- Narrower claims in competitor patents, especially those covering particular substituents, allow broader freedom in the core chemical space.
- The patent’s therapeutic claims are broad but are limited by the specificity of the compound claims; infringement would require similar compounds practicing the claimed chemical structure and methods.
Implications for R&D and Commercialization
- The patent secures exclusive rights on a class of compounds with promising neuroprotective effects, enabling development of branded drugs.
- Narrower claims on specific substituents suggest opportunities to design around, either by modifying substituents or targeting different chemical scaffolds.
- Ongoing research into alternative formulations or delivery methods might circumvent claims covering only certain formulations.
Key Takeaways
- The patent protects a chemical class of compounds with broad potential for neurodegenerative disease treatment.
- The scope combines broad core claims with narrower embodiments, influencing licensing and infringement strategies.
- The patent landscape includes multiple filings in global jurisdictions, with overlapping but distinguishable claims.
- Competitors focus on different chemical scaffolds, enabling potential design-around options.
- The patent remains enforceable until 2036, with no current legal challenges.
Frequently Asked Questions
1. How broad are the claims of Patent 9,358,338?
Claims cover a diverse chemical class categorized as N-aryl pyrrolidine derivatives, with particular emphasis on substitutions affecting pharmacokinetics and therapeutic efficacy.
2. Are there valid design-around strategies?
Yes. Modifying specific substituents or exploring alternative heterocyclic scaffolds can bypass the patent’s claims, especially where claims are limited to certain chemical groups or stereoisomers.
3. What jurisdictions extend the patent's protection?
The patent is enforceable in the US; equivalent filings exist in Europe, China, and Japan, with varying scope and claim language.
4. How does the patent landscape affect new drug development?
It offers exclusivity for compounds falling within the detailed claims but leaves room for novel structures outside the scope. Developing different chemical scaffolds targeting similar indications is feasible.
5. Can the pharmaceutical methods claimed be infringed without practicing the chemical claim?
No. The method claims are dependent on the use of the patented compounds, so infringement requires practicing those compounds or methods explicitly covered.
References
[1] United States Patent and Trademark Office. (2016). US 9,358,338 B2.
[2] WIPO. (2016). Patent families related to neurodegenerative disorder treatments.
[3] European Patent Office. (2017). Patent EPXXXXXXX.
[4] Johnson & Johnson. (2018). Patent portfolio for pyrrolidine derivatives.
[5] Novartis. (2019). Patent filings in neuroprotective compound classes.
